Intuitive Surgical
ISRG
$417.07
+0.12%
Intuitive Surgical Inc. is a global leader in robotic-assisted minimally invasive surgery, primarily through its da Vinci surgical systems, which are complemented by a recurring revenue stream from instruments, accessories, and services. The company is the dominant market leader in robotic surgery, with a formidable competitive moat built on a vast installed base of over 10,000 systems, extensive surgeon training, and a deep portfolio of clinical applications. The current investor narrative is centered on its ability to sustain robust growth against emerging competition, such as Medtronic's Hugo system, while navigating potential regulatory headwinds, as evidenced by recent FDA safety concerns over a stapler product, and its capacity to continue expanding procedural volumes globally.…
ISRG
Intuitive Surgical
$417.07
Related headlines
Investment Opinion: Should I buy ISRG Today?
Rating & Thesis: Hold. ISRG is a high-quality company with a superb business model, but its premium valuation and persistent technical weakness create a poor near-term risk/reward profile, warranting patience. This aligns with a neutral stance, acknowledging the 45% implied upside to analyst targets but requiring a catalyst for realization.
Supporting Evidence: The hold rating is supported by four key data points: 1) The forward P/E of 34.9x represents a significant premium to the medical device sector, limiting near-term upside. 2) While revenue growth is robust at 18.8% YoY, the stock's 1-year price decline of -19.9% shows the market is prioritizing valuation over growth. 3) Profitability metrics are exceptional (66.4% gross margin, 30.2% operating margin), but these are already well-known and priced in. 4) Analyst consensus suggests a $595 target (45% upside), but the wide EPS estimate range ($16.41 to $18.17) reflects material uncertainty about future execution.
Risks & Conditions: The two biggest risks are multiple compression from its premium valuation and market share erosion from emerging competition. This Hold would upgrade to a Buy if the forward P/E compresses to near 30x (approximately $512) on sustained growth, or if the stock establishes a clear technical reversal above key resistance. It would downgrade to a Sell if revenue growth decelerates below 15% or if operating margins show sustained contraction. Relative to its own history and peers, the stock is overvalued, but it is fairly valued for its unique growth profile if estimates are met; thus, it is a 'GARP at a price' situation.
Sign up to view all
ISRG 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The fundamental business is undeniably strong, but the stock is a victim of its own prior success and premium valuation in a less forgiving market environment. The path of least resistance in the next 12 months is likely sideways to modestly higher (base case), as the company must prove it can grow into its valuation. A catalyst for a bullish re-rating is not immediately visible, while the bear case, though lower probability, carries significant downside due to the valuation air pocket. The stance would upgrade to bullish on a confirmed technical reversal above $450 coupled with sustained double-digit revenue growth, or downgrade to bearish on a breakdown below $395 with deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intuitive Surgical's 12-month outlook, with a consensus price target around $542.19 and implied upside of +30.0% versus the current price.
Average Target
$542.19
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$334 - $542
Analyst target range
The stock is covered by 15 analysts, and the consensus sentiment leans bullish, as evidenced by recent actions from firms like Citigroup and Freedom Capital Markets upgrading to 'Buy' or 'Overweight'. The average analyst target price is implied by the estimated EPS of $17.08 and the forward P/E of 34.86, which suggests a target of approximately $595, representing a potential upside of about 45% from the current price of $411.06. The target range is wide, with estimated EPS spanning from a low of $16.41 to a high of $18.17, reflecting differing assumptions about growth execution, competitive pressures, and margin sustainability. The high target assumes successful market expansion and sustained premium valuations, while the low target likely factors in increased competition or regulatory setbacks. The recent institutional rating actions show a mix of reaffirmations and selective upgrades, indicating underlying confidence in the long-term story despite the stock's recent technical weakness.
Bulls vs Bears: ISRG Investment Factors
The investment debate for ISRG centers on a powerful fundamental business trapped in a severe valuation and sentiment correction. The bull case, supported by robust 18.8% revenue growth, a dominant moat, and stellar profitability, currently contends with the stronger bearish evidence of a persistent technical breakdown and an extreme valuation premium that is compressing. The single most important tension is whether the company's projected earnings growth can materialize quickly enough to justify and sustain its premium multiple in the face of rising competition and a market that has punished high-PE stocks. The resolution of this growth-vs-valuation conflict will determine the stock's direction.
Bullish
- Robust Revenue Growth and Recurring Model: Q4 2025 revenue grew 18.76% YoY to $2.87B, driven by the fast-growing Instruments & Accessories segment ($1.66B). This demonstrates strong underlying demand and a sticky, high-margin recurring revenue stream that accounts for over 70% of total sales.
- Dominant Market Position and Moat: With an installed base of over 10,000 da Vinci systems, the company benefits from a powerful network effect. Surgeon training and clinical application depth create significant switching costs, presenting a formidable barrier to new entrants like Medtronic's Hugo.
- Exceptional Profitability and Cash Generation: The company maintains industry-leading gross margins of 66.44% and generates substantial free cash flow ($2.49B TTM). A pristine balance sheet with a debt-to-equity ratio of 0.017 and a current ratio of 4.87 provides immense financial flexibility.
- Analyst Confidence and Significant Upside: The consensus analyst target price, implied by a forward P/E of 34.86x and estimated EPS of $17.08, is approximately $595. This represents a potential 45% upside from the current price of $411.06, with recent upgrades signaling long-term conviction.
Bearish
- Extreme Valuation Premium and Compression Risk: The stock trades at a forward P/E of 34.9x, a significant premium to typical medical device industry averages (20-25x). Its trailing P/E of 70.8x is near the upper end of its historical range, leaving little room for multiple expansion and high sensitivity to growth disappointments.
- Persistent Technical Downtrend and Weak Momentum: The stock is down 19.87% over the past year and 24.20% over six months, underperforming the SPY by 42.73%. Trading near its 52-week low of $396.68, it exhibits a clear downtrend with a high beta of 1.45, indicating elevated volatility and continued negative momentum.
- Intensifying Competitive and Regulatory Threats: Medtronic's FDA approval for its Hugo system marks a credible competitive entry. Concurrently, recent FDA safety concerns over a stapler product highlight regulatory headwinds that could impact reputation, sales, and margins.
- High Growth Expectations Priced In: The market is pricing in near-perfect execution, with the forward P/E implying sustained high growth. Any deceleration from the current 18.8% revenue growth rate or margin pressure could trigger a severe derating given the elevated PEG ratio of 3.17.
ISRG Technical Analysis
The stock is in a pronounced downtrend, with a 1-year price change of -19.87% and a 6-month decline of -24.20%. Currently trading at $411.06, it sits near the lower end of its 52-week range ($396.68 to $603.88), positioning it at approximately 68% of the range, which suggests the stock is in value territory but could also indicate a 'falling knife' scenario given the persistent negative momentum. Recent momentum shows continued weakness, with the stock down 4.91% over the past month and 12.94% over the past three months, confirming the longer-term bearish trend without signs of a meaningful reversal. The stock's beta of 1.453 indicates it is approximately 45% more volatile than the broader market, which has significantly outperformed it, as shown by a 1-year relative strength of -42.73% versus the SPY. Key technical levels are clear: the 52-week low of $396.68 serves as critical near-term support, while the 52-week high of $603.88 represents formidable resistance; a sustained breakdown below support could trigger further selling, while a recovery above it would be the first step toward stabilizing the price action.
Beta
1.45
1.45x market volatility
Max Drawdown
-32.1%
Largest decline past year
52-Week Range
$397-$604
Price range past year
Annual Return
-19.6%
Cumulative gain past year
| Period | ISRG Return | S&P 500 |
|---|---|---|
| 1m | -1.0% | +1.5% |
| 3m | -12.7% | +13.4% |
| 6m | -25.8% | +10.9% |
| 1y | -19.6% | +24.5% |
| ytd | -25.8% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ISRG Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue of $2.87 billion representing a year-over-year increase of 18.76%, continuing a multi-quarter trend of strong double-digit growth. The revenue segment breakdown shows Instruments and Accessories ($1.66B) as the largest and fastest-growing segment, followed by Systems ($785.9M) and Services ($422M), indicating a healthy, recurring revenue-driven business model. The company is highly profitable, with Q4 2025 net income of $794.8 million and a gross margin of 66.44%, which has remained stable and industry-leading over recent quarters. Operating margins are also strong at 30.15% for the quarter, demonstrating efficient scaling of its high-margin business. The balance sheet is exceptionally strong, with a debt-to-equity ratio of just 0.017, indicating minimal financial leverage, and a robust current ratio of 4.87 ensuring ample liquidity. The company generates substantial cash flow, with trailing twelve-month free cash flow of $2.49 billion and an ROE of 16.02%, showcasing its ability to fund growth internally and deliver strong returns on shareholder equity.
Quarterly Revenue
$2.9B
2025-12
Revenue YoY Growth
+0.18%
YoY Comparison
Gross Margin
+0.66%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ISRG Overvalued?
Given the company's substantial profitability, the primary valuation metric is the P/E ratio. The trailing P/E is elevated at 70.78x, while the forward P/E is significantly lower at 34.86x, indicating the market is pricing in strong future earnings growth, with analysts expecting EPS to rise from $2.24 to an estimated $17.08. Compared to sector averages, the stock trades at a significant premium; for instance, its forward P/E of 34.9x is well above typical medical device industry averages (often in the 20-25x range), a premium justified by its superior growth profile, market dominance, and high margins. Historically, the stock's current trailing P/E of 70.8x is near the upper end of its own historical range observed over the past several years, which has typically fluctuated between approximately 50x and 85x, suggesting the market's expectations are already optimistic and may limit near-term multiple expansion potential.
PE
70.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 49x~84x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
49.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ISRG's primary financial risk is not leverage or liquidity—its balance sheet is fortress-like with minimal debt—but rather valuation dependency on flawless execution. The forward P/E of 34.9x demands that the company hit its estimated EPS of $17.08 and maintain high growth. A slowdown in procedure volumes, margin contraction from competitive pricing, or a significant product recall (like the recent FDA stapler concern) could severely impact earnings and trigger a multiple derating. The company's revenue, while diversified across segments, remains heavily reliant on the continued adoption and utilization of its da Vinci platform, creating concentration risk within the robotic surgery niche.
Market & Competitive Risks: The stock faces acute market risk due to its premium valuation and high beta of 1.45. Trading at a ~40% premium to sector averages on a forward P/E basis, it is vulnerable to compression if growth stock multiples contract or if sector rotation continues. The competitive landscape is intensifying with Medtronic's Hugo system now FDA-approved, threatening ISRG's pricing power and market share over the long term, though its massive installed base provides a near-term buffer. Regulatory scrutiny, as highlighted by recent news, adds another layer of uncertainty that could dampen investor sentiment and increase compliance costs.
Worst-Case Scenario: The worst-case scenario involves a perfect storm: a significant slowdown in system placements and procedure growth due to economic pressures or competition, coupled with a margin-compressing price war and a further regulatory setback. This could lead to earnings missing estimates, causing a severe derating of the forward P/E towards the sector average of ~22x. Applying that multiple to a depressed EPS estimate of $16.41 (analyst low) suggests a downside target near $361. From the current price of $411.06, a break below the 52-week low of $396.68 could trigger accelerated selling, with a realistic downside risk of -20% to -25%, potentially reaching the mid-$300s.
FAQ
The key risks are: 1) Valuation Compression: The primary risk is its high forward P/E of 34.9x; any growth scare could trigger a severe derating. 2) Competitive Disruption: Medtronic's FDA-approved Hugo system represents the most credible long-term threat to its monopoly pricing power. 3) Regulatory & Product Safety: Recent FDA flags on a stapler product highlight operational risks that could impact sales and reputation. 4) Macro & Sentiment: With a beta of 1.45, the stock is highly volatile and vulnerable to sector rotation away from expensive growth stocks, as seen in its 42.7% underperformance vs. the SPY over the past year.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $480 and $550 as it grinds higher on earnings growth, aligning with the analyst average target. The Bull Case (25% probability) projects a rally to $580-$603 on exceeded expectations and renewed investor enthusiasm. The Bear Case (15% probability) warns of a drop to $360-$400 if growth stumbles and the multiple contracts sharply. The most likely outcome is the Base Case, contingent on the company meeting its estimated EPS of $17.08 without major setbacks.
ISRG is overvalued on an absolute trailing basis (P/E of 70.8x) but arguably fairly valued on a forward-looking basis if growth targets are met (forward P/E of 34.9x). However, this forward multiple still represents a significant premium of approximately 40-50% over the typical medical device sector average. The market is paying a premium price for premium growth and market dominance. The valuation implies the market expects near-flawless execution of double-digit revenue growth and margin stability for the foreseeable future, leaving little room for error.
ISRG is a good stock for a specific type of investor: those with a long-term horizon and high conviction in robotic surgery adoption. For new money today, it presents a dilemma. The analyst-implied upside of 45% to ~$595 is compelling, but it requires the company to hit aggressive earnings targets while navigating rising competition. The stock's 20% decline over the past year and high valuation premium increase near-term risk. It is a 'good buy' for patient investors seeking to dollar-cost average into a leader, but a risky proposition for short-term traders given its volatile downtrend.
ISRG is unequivocally a long-term investment, unsuitable for short-term trading. Its high beta (1.45) and current downtrend make it far too volatile for short-term holders. The investment thesis is based on the multi-year secular adoption of robotic surgery, the expansion of its installed base, and the compounding of high-margin recurring revenue. There is no dividend, so total return relies entirely on capital appreciation. Given the valuation recalibration underway, investors should be prepared to hold for a minimum of 3-5 years to allow the business growth to overcome near-term multiple compression and volatility.
